A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no approved treatment. Resmetirom is an oral, liver-directed, thyroid hormone receptor beta-selective agonist in development for the treatment of NASH with liver fibrosis. METHODS: We are conducting an ongoing phase 3 trial involving adults with biopsy-confirmed NASH and a fibrosis stage of F1B, F2, or F3 (stages range from F0 [no fibrosis] to F4 [cirrhosis]). Patients were randomly assigned in a 1:1:1 ratio to receive once-daily resmetirom at a dose of 80 mg or 100 mg or placebo. The two primary end points at week 52 were NASH resolution (including a reduction in the nonalcoholic fatty liver disease [NAFLD] activity score by ≥2 points; scores range from 0 to 8, with higher scores indicating more severe disease) with no worsening of fibrosis, and an improvement (reduction) in fibrosis by at least one stage with no worsening of the NAFLD activity score. RESULTS: Overall, 966 patients formed the primary analysis population (322 in the 80-mg resmetirom group, 323 in the 100-mg resmetirom group, and 321 in the placebo group). NASH resolution with no worsening of fibrosis was achieved in 25.9% of the patients in the 80-mg resmetirom group and 29.9% of those in the 100-mg resmetirom group, as compared with 9.7% of those in the placebo group (P<0.001 for both comparisons with placebo). Fibrosis improvement by at least one stage with no worsening of the NAFLD activity score was achieved in 24.2% of the patients in the 80-mg resmetirom group and 25.9% of those in the 100-mg resmetirom group, as compared with 14.2% of those in the placebo group (P<0.001 for both comparisons with placebo). The change in low-density lipoprotein cholesterol levels from baseline to week 24 was -13.6% in the 80-mg resmetirom group and -16.3% in the 100-mg resmetirom group, as compared with 0.1% in the placebo group (P<0.001 for both comparisons with placebo). Diarrhea and nausea were more frequent with resmetirom than with placebo. The incidence of serious adverse events was similar across trial groups: 10.9% in the 80-mg resmetirom group, 12.7% in the 100-mg resmetirom group, and 11.5% in the placebo group. CONCLUSIONS: Both the 80-mg dose and the 100-mg dose of resmetirom were superior to placebo with respect to NASH resolution and improvement in liver fibrosis by at least one stage. (Funded by Madrigal Pharmaceuticals; MAESTRO-NASH ClinicalTrials.gov number, NCT03900429.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Therefore, incretinbased medications for the treatment of MASLD could be made available, supplementing resmetirom as the only approved medication in the USA and Europe.87”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [87]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Resmetirom is the first compound approved for the treatment of MASH in conjunction with diet and exercise, showing the importance of combining lifestyle changes to pharmacological treatment.91”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [91]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It was not until March 2024 that the U.S. Food and Drug Administration (FDA) approved the first drug, Rezdiffra, for non-alcoholic steatohepatitis (NASH) with liver fibrosis.”
From Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells (2025) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Resmetirom, a THRβ agonist, showed antisteatogenic potential in a 36-week phase 2 RCT in people with biopsy-confirmed MASH and fibrosis, accompanied by a rise in circulating adiponectin and improved plasma lipid profile [210,211].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [211]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“About 14% of participants in the MAESTRO-NASH trial were on GLP1RA treatment, with stable dosage in the 6 months and stable body weight in the 3 months preceding screening liver biopsy.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [350]
Experimental — accuracy not yet measured
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationMach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citationAlberti, K. G. M. M., Zimmet, P., & Shaw, J. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.01858.x · Cited by 6,597
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000520 · Cited by 3,476
Self-citationAngulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Self-citationEstes, C., Razavi, H., Loomba, R., Younossi, Z., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29466 · Cited by 2,399
Self-citationMechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
Self-citation
Research works printed but not linked: 2
- 24. Conduct of clinical trials of medical products during the COVID-19 public health emergency: guidance for industry, investigators, and institutional review boards. Silver Spring, MD: Food and Drug Administration, August 30, 2021 (https:// www . fda . gov/ media/ 136238/ download/ ). Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the
- 3. ogy/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: 2935-59.
Cited by
Items 201–300 of 1,003
Research advances in the diagnosis and treatment of MASLD/MASH
Wang, D., Miao, J., Zhang, L., & Zhang, L. (2024) · Annals of Medicine · doi:10.1080/07853890.2024.2445780 · Cited by 47
Cardiovascular, Kidney, Liver, and Metabolic Interactions in Heart Failure: Breaking Down Silos
Lee, C. J. M., Kosyakovsky, L. B., Khan, M. S., Wu, F., Chen, G., Hill, J. A., Ho, J. E., Foo, R., & Zannad, F. M. (2025) · Circulation Research · doi:10.1161/circresaha.125.325602 · Cited by 40
MASLD, MASH, and the CKM Spectrum
Zannad, F. M., Khan, M. S., Bansal, N., Böhm, M., Francque, S., Girerd, N., Januzzi, J. L., Miller, V., Piché, M., Ratziu, V., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.12.015 · Cited by 40
Self-citationNAFLD in the 21st Century: Current Knowledge Regarding Its Pathogenesis, Diagnosis and Therapeutics
Kounatidis, D. C., Vallianou, N. G., Geladari, E. V., Panoilia, M.-P., Daskou, A., Stratigou, T., Karampela, Ι., Tsilingiris, D., & Dalamaga, Μ. (2024) · Biomedicines · doi:10.3390/biomedicines12040826 · Cited by 40
“In addition, other drugs are under investigation for NASH, among which pegozafer-min and resmetiron seem to be very promising [101–105].”
BackgroundEHBP1 suppresses liver fibrosis in metabolic dysfunction-associated steatohepatitis
Ma, F., Longo, M., Meroni, M., Bhattacharya, D., Paolini, E., Mughal, S., Hussain, S., Anand, S. K., Gupta, N., Zhu, Y., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.01.020 · Cited by 29
Albert, S. G., & Wood, E. M. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108777 · Cited by 36
Regulation of Fructose Metabolism in Nonalcoholic Fatty Liver Disease
Lodge, M., Dykes, R., & Kennedy, A. J. (2024) · Biomolecules · doi:10.3390/biom14070845 · Cited by 38
“Resmetirom is the only therapy for NASH approved by the U.S. Food and Drug Administration (FDA), but it remains to be seen if this therapy will lead to long-term complications or side effects [29].”
BackgroundNAFLD and NAFLD Related HCC: Emerging Treatments and Clinical Trials
Khare, T., Liu, K., Chilambe, L. O., & Khare, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26010306 · Cited by 34
Arvanitakis, K., Koufakis, T., Cholongitas, Ε., Francque, S., & Germanidis, G. S. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108811 · Cited by 37
Self-citationBerdowska, I., Matusiewicz, M., & Fecka, I. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062394 · Cited by 35
Jackson, E., Dennis, A., Alkhouri, N., Samala, N. R., Vuppalanchi, R., Sanyal, A. J., Muthiah, M. D., Banerjee, R., & Banerjee, A. (2025) · Nature Medicine · doi:10.1038/s41591-025-03654-2 · Cited by 31
“Resmetirom 10 , the first therapeutic indication for MASH, received accelerated regulatory approval in 2024, and antiobesity drugs are also being considered 11,12 .”
Self-citationSuresh, M. G., Mohamed, S., Geetha, H. S., Prabhu, S., Trivedi, N., Ng, Z. C., Mehta, P. D., Brar, A. S., Sohal, A., Goyal, M. K., et al. (2026) · World Journal of Diabetes · doi:10.4239/wjd.v17.i2.113149 · Cited by 36
“…under historical NASH definitions), resmetirom achieved: (1) Significantly higher rates of NASH resolution without worsening fibrosis; (2) Significant fibrosis improvement without worsening NASH; and (3) Reductions in low density lipoprotein cholesterol and hepatic fat on MRI-PDFF[123,124].”
Modeling the health and economic impact of pharmacologic therapies for MASLD in the United States
Wallace, C., Gamkrelidze, I., Estes, C., Razavi, H., & Sanyal, A. J. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.01.009 · Cited by 27
Self-citationZhang, G. Y., & Brandman, D. (2025) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.6431 · Cited by 27
Elucidating cuproptosis in metabolic dysfunction-associated steatotic liver disease
Li, Y., Qi, P., Song, S., Wang, Y., Wang, H., Cao, P., Liu, Y., & Wang, Y. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116585 · Cited by 30
Wang, Y., Zhou, J., Yang, Q., Li, X., Qiu, Y., Zhang, Y., Liu, M., & Zhu, A. J. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100635 · Cited by 35
Nie, Y., Zhou, W., Niu, T., Mao, M., Zhan, Y., Li, Y., Wang, K., Li, M., & Ding, K. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01454-x · Cited by 31
Abdelhameed, F., Mustafa, A., Kite, C., Lagojda, L., Dallaway, A., Than, N. N., Kassi, E. N., Kyrou, I., & Randeva, H. S. (2025) · Livers · doi:10.3390/livers5010011 · Cited by 37
Misra, A., Kumar, A., Kuchay, M. S., Ghosh, A., Gulati, S., Choudhary, N. S., Dutta, D., Sharma, P., Vikram, N. K., Rastogi, A., et al. (2025) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2025.103209 · Cited by 28
Accacha, S. D., Barillas, J., Srivastava, A., Ross, F., Drewes, W., Gulkarov, S., Leon, J. D., & Reiss, A. B. (2025) · Metabolites · doi:10.3390/metabo15050287 · Cited by 39
“MASH resolution with no worsening of fibrosis, and an improvement in fibrosis by ≥ 1 stage with no worsening of the NAFLD activity score, was achieved in significantly more patients who received resmetirom than in those who received placebo at week 52 [246].”
Zhao, Y., Bo, Y., Zu, J., Xing, Z., Yang, Z., Zhang, Y., Deng, Y., Liu, Y., Zhang, L., Yuan, X., et al. (2025) · Liver International · doi:10.1111/liv.70155 · Cited by 37
“The recent approval of the first medication for MASLD with fibrosis stages 1–3, along with anticipated future agents, may contribute to a decline in the incidence and death of MASLD-related cirrhosis [28, 29].”
The pathogenesis of hepatic steatosis in MASLD: a lipid droplet perspective
Krahmer, N., Walther, T. C., & Farese, R. V. (2025) · Journal of Clinical Investigation · doi:10.1172/jci198334 · Cited by 35
“Resmetirom, the first FDA-approved drug for MASH and a liver-specific thyroid hormone receptor agonist (25), also targets hepatic lipid metabolism.”
Zhou, X., Fan, Q.-Y., Byrne, C. D., Targher, G., Muthiah, M. D., Huang, D. Q., Chen, Q., Noureddin, M., Li, W., Ratziu, V., et al. (2025) · Gut · doi:10.1136/gutjnl-2025-337431 · Cited by 44
Self-citationKanwal, F., Bril, F., Wong, V. W., Adams, L. A., Pfotenhauer, K. M., SKOLNIK, N., Wright, E. E., Eckel, R. H., Noureddin, M., Loomba, R. S., et al. (2026) · Gastroenterology · doi:10.1053/j.gastro.2026.01.047 · Cited by 47
Self-citationRinella, M. E., & Sookoian, S. C. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-026-01187-8 · Cited by 34
“Conversely, some individuals with less pronounced PDFF improvements nonetheless demonstrated histological benefit 9 .”
InfluentialSelf-citationCyclophilin inhibition as a strategy for the treatment of human disease
Stauffer, W. T., Goodman, A. Z., & Gallay, P. A. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1417945 · Cited by 31
Das, S. R., Finney, A. C., Anand, S. K., Rohilla, S., Liu, Y., Pandey, N. O., Ghrayeb, A., Kumar, D., Núñez, K., Liu, Z., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01134-4 · Cited by 31
“Despite major advances in our understanding of the metabolic and molecular mechanisms driving MASH, and considerable efforts in the development of drugs targeting lipid and carbohydrate metabolism, there is limited pharmacological therapy available for the treatment of MASH 6,7 .”
Ktenopoulos, N., Sagris, Μ., Gerogianni, M., Pamporis, K., Apostolos, A., Balampanis, K., Tsioufis, K. P., Toutouzas, K. P., & Tousoulis, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910595 · Cited by 33
“Based on these results, resmetirom has become the first FDA approved agent for the treatment of adults with NASH with moderate to advanced liver fibrosis, to be used along with diet and exercise [116].”
BackgroundKaylan, K. B., & Paul, S. (2024) · Current Diabetes Reports · doi:10.1007/s11892-024-01558-y · Cited by 34
“…resolution in 29.9% and fibrosis improvement in 25.9% of patients with MASH compared to 9.7% and 14.2% respec - tively in the placebo group [ 49 ], leading to Federal Drug Administration (FDA) approval for MASH under the accelerated approval pathway for patients with MASH and F2 or F3…”
InfluentialCastañé, H., Jiménez-Franco, A., Hernández‐Aguilera, A., Martínez-Navidad, C., Cambra-Cortés, V., Onoiu, A.-I., Jiménez-Aguilar, J. M., París, M., Hernández, M., Parada, D., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105532 · Cited by 34
Bile acids and their receptors in hepatic immunity
Fiorucci, S., Marchianò, S., Distrutti, E., & Biagioli, M. (2025) · Liver Research · doi:10.1016/j.livres.2025.01.005 · Cited by 31
Jain, P., Jain, A., Deshmukh, R., Samal, P. K., Satapathy, T., & Ajazuddin, M. (2025) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2025.102584 · Cited by 32
The barriers to uptake of artificial intelligence in hepatology and how to overcome them
Clusmann, J., Balaguer‐Montero, M., Bassegoda, O., Schneider, C. V., Seraphin, T. P., Paintsil, E. K., Luedde, T., Pérez-López, R., Caldéraro, J., Gilbert, S., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.07.003 · Cited by 34
RetractedRomanos, M., Cordova, J. M. G., Villamarin, J. L., Zurita, J. D. P., & Acosta, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70659 · Cited by 35
CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes
Schnell, O., Barnard-Kelly, K. D., Battelino, T., Ceriello, A., Larsson, H. E., Fernández‐Fernández, B., Forst, T. M., Frías, J. P., Gavin, J. R., Giorgino, F., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02180-8 · Cited by 29
“However, Phase III clinical trials with resmetirom, a thyroid hormone receptor beta agonist, showed positive results [92] and resmetirom has been submitted to the FDA for approval, with a decision expected in March 2024.”
BackgroundFan, W., Bradford, T. M., & Török, N. J. (2024) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15184 · Cited by 25
Resmetirom and GLP-1 agonists for MASH: complementary rather than exclusive
Zhou, X., Wong, V. W., & Zheng, M. (2024) · npj gut and liver. · doi:10.1038/s44355-024-00004-w · Cited by 29
Drug treatment for metabolic dysfunction-associated steatotic liver disease: Progress and direction
Zhou, D., & Fan, J. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003355 · Cited by 30
Huang, Q., An, Z., Xin, X., Gou, X., Tian, X., Hu, Y., Mei, Z., & Feng, Q. (2024) · Food Science & Nutrition · doi:10.1002/fsn3.4595 · Cited by 32
Youhanna, S. C., Kemas, A. M., Wright, S. C., Zhong, Y., Klumpp, B., Klein, K., Motso, A., Michel, M., Ziegler, N., Shang, M.-M., et al. (2024) · Advanced Science · doi:10.1002/advs.202407572 · Cited by 41
Monti, E., Vianello, C., Leoni, I., Galvani, G., Lippolis, A., D’Amico, F., Roggiani, S., Stefanelli, C., Turroni, S., & Fornari, F. (2025) · Cells · doi:10.3390/cells14020084 · Cited by 36
“Indeed, despite the recent approval of Resmetirom for MAFLD treatment [90,91], information regarding HCC prevention is not yet available.”
At the Crossroads of Health and Disease: Consequences of Fat in the Liver
Dukewich, M., Yuan, L., & Terrault, N. A. (2025) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022724-105515 · Cited by 39
Liu, H., Lefere, S., Guillot, A., Zheng, M., & Tacke, F. (2025) · Hepatology · doi:10.1097/hep.0000000000001417 · Cited by 44
Strandberg, R., Åberg, F. O., Asteljoki, J. V., Luukkonen, P. K., Salomaa, V. V., Jula, A., Lundqvist, A., Männistö, S., Perola, M., Talbäck, M., et al. (2025) · BMJ · doi:10.1136/bmj-2024-083182 · Cited by 38
“10 Patients with screening detected compensated cirrhosis may benefit from surveillance for oesophageal varices and hepatocellular carcinoma, for example.”
HFpEF and MASLD: converging mechanisms and clinical implications
Capone, F., Häseli, S. P., Liu, L., Strocchi, S., Langenberg, C., Lusis, A. J., Pietzner, M., Muoio, D. M., Rider, O. J., Raman, B., et al. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01257-z · Cited by 37
“Resmetirom promoted steatohepatitis resolution and reduced fibrosis compared with placebo in the MAESTRO-NASH trial 410 , and improved MRI-PDFF scores and reduced liver stiffness without affecting heart rate or causing arrhythmias in the MAESTRO-NAFLD trial 411 .”
Pοlyzos, S. A., & Mantzoros, C. S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155936 · Cited by 26
Hepatic mitochondrial reductive stress in the pathogenesis and treatment of steatotic liver disease
Jokinen, M. J., & Luukkonen, P. K. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.02.003 · Cited by 27
Au, K., Zheng, M.-H., Lee, W., Ghanem, O. M., Mahawar, K. K., Shabbir, A., le Roux, C. W., Targher, G., Byrne, C. D., Yilmaz, Y., et al. (2024) · Current Obesity Reports · doi:10.1007/s13679-024-00582-z · Cited by 26
“Both doses of resmetirom were superior to placebo concerning MASH resolution and improved liver fibrosis by at least one stage [15], it has potential, safety and efficacy in the treatment of MASH.”
InfluentialKAHL, S., Straßburger, K., Pacini, G., Trinks, N., Pafili, K., Mastrototaro, L., Dewidar, B., Sarabhai, T., Trenkamp, S., Esposito, I., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.08.012 · Cited by 30
Shen, D., Cai, X., Hu, J., Song, S., Zhu, Q., Ma, H., Zhang, Y., Ma, R., Zhou, P., Yang, W., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1451383 · Cited by 25
Inter-organ metabolic interaction networks in non-alcoholic fatty liver disease
Fan, Y., Zhang, S., Wang, Y., Wang, H., Li, H., & Bai, L. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1494560 · Cited by 28
Cheah, M. C. C., Crane, H., & George, J. (2025) · Hepatology International · doi:10.1007/s12072-025-10801-x · Cited by 37
“This might require a more nuanced approach to treatment with dose reduction of weight loss agents such as GLP1-RA (where needed), possibly in combination with agents that also improve lipid and glycemic profiles but having minimal effects on weight such as resmetirom [20] and FGF21 analogues [22].”
Feng, G., Wong, V. W., Targher, G., Byrne, C. D., & Zheng, M. (2025) · Gut · doi:10.1136/gutjnl-2025-335542 · Cited by 37
Younossi, Z. M., Germani, G., Wong, R. J., Stepanova, M., Nader, F., Karam, V. H., Adam, R. A., Alqahtani, S. A., Henry, L. L., & Burra, P. (2025) · Liver Transplantation · doi:10.1097/lvt.0000000000000688 · Cited by 24
Self-citationPresent and Future Perspectives in the Treatment of Liver Fibrosis
Cerrito, L., Galasso, L., Iaccarino, J., Pizzi, A., Termite, F., Esposto, G., Borriello, R., Ainora, M. E., Gasbarrini, A., & Zocco, M. A. (2025) · Pharmaceuticals · doi:10.3390/ph18091321 · Cited by 35
“This molecule provided better results compared to placebo in the reduction in inflammation and in the reduction in fibrosis progression [159].”
Sarcopenia and MASLD: novel insights and the future
Liu, C., Zeng, Q., Kim, W. K., Kim, S. U., Younossi, Z. M., Targher, G., Byrne, C. D., Mantzoros, C. S., Charatcharoenwitthaya, P., Leclercq, I. A., et al. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01197-7 · Cited by 43
“As the first approved treatment for non-cirrhotic MASH with moderate-to-advanced fibrosis, resmetirom has shown efficacy in reducing liver lipid content and improving histological features of MASH in phase III MAESTRO clinical trials 138,139 .”
Self-citationByrne, C. D., & Targher, G. (2024) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.06 · Cited by 27
Longo, M., Paolini, E., Benedetto, P. D., Tomassini, E., Meroni, M., & Dongiovanni, P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25169074 · Cited by 25
“While lifestyle changes are the cornerstone for MASLD management, at the beginning of 2024, the first pharmacological treatment was approved by the US Food and Drug Administration (FDA) [8].”
BackgroundStatin use and liver-related prognosis among patients with MASLD
Yun, B., Park, H., Lee, J., Kim, B. K., & Yoon, J. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101313 · Cited by 35
Disease classification, diagnostic challenges, and evolving clinical trial design in MASLD
Lauridsen, M. M., Ravnskjær, K., Gluud, L. L., & Sanyal, A. J. (2025) · Journal of Clinical Investigation · doi:10.1172/jci189953 · Cited by 34
“These tests also have lower accuracy for diagnosing the intermediate levels of fibrosis (F2–F3), which are potentially eligible for treatment (44, 45).”
Self-citationA call for doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitis
Lazarus, J. V., Brennan, P., Mark, H. E., Alazawi, W., Allen, A. M., Byrne, C. D., Castéra, L., Caussy, C., Cusi, K. J., Grajower, M. M., et al. (2025) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2025.101320 · Cited by 34
Self-citationNoureddin, M., Alkhouri, N., Lawitz, E., Kowdley, K. V., Loomba, R., Lee, L. K., Jones, C. T., Schlegel, A., Marmon, T., Anderson, K., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03722-7 · Cited by 31
“However, data from previous THRβ agonist studies in MASH populations indicate that such differences in baseline characteristics are not expected to have impacted our study results 19,29,52,53 .”
InfluentialSelf-citationGoto, H., & Takamura, T. (2025) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes25017 · Cited by 30
“80 Additionally, genome-wide association studies have identified several susceptibility genes for MASLD/MASH, providing new insights into disease pathophysiology and potential therapeutic strategies.”
Hepatic adaptation to chronic metabolic stress primes tumorigenesis
Tzouanas, C. N., Shay, J. E. S., Sherman, M. S., Rubin, A. J., Mead, B. E., Dao, T. T., Tao, J., Lehrich, B. M., Eng, G. M., Patterson-Fortin, J., et al. (2025) · Cell · doi:10.1016/j.cell.2025.11.031 · Cited by 39
Review article: Hepatic steatosis and its associations with acute and chronic liver diseases
Koenig, A. B., Tan, A., Abdelaal, H., Monge, F., Younossi, Z. M., & Goodman, Z. D. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18059 · Cited by 30
Self-citationElshaer, A., Chascsa, D. M. H., & Lizaola‐Mayo, B. (2024) · Life · doi:10.3390/life14070844 · Cited by 32
“Additionally, the study demonstrated improvement in liver fibrosis by at least one stage without worsening the nonalcoholic fatty liver disease activity score [98].”
BackgroundAntwi, M. B., Jennings, A., Lefere, S., Clarisse, D., Geerts, A. M., Devisscher, L., & Bosscher, K. D. (2024) · npj Metabolic Health and Disease · doi:10.1038/s44324-024-00013-6 · Cited by 27
Immunological dynamics in MASH: from landscape analysis to therapeutic intervention
Rabiu, L., Zhang, P., Afolabi, L. O., Saliu, M. A., Dabai, S. M., Suleiman, R. B., Gidado, K. I., Ige, M. A., Ibrahim, A., Zhang, G., et al. (2024) · Journal of Gastroenterology · doi:10.1007/s00535-024-02157-0 · Cited by 26
“Until recently, the FDA and EMA had not approved any drugs specifically for the treatment of MASH [123].”
Kaji, K., Takeda, S., Iwai, S., Nishimura, N., Sato, S., Namisaki, T., Akahane, T., & Yoshiji, H. (2024) · Antioxidants · doi:10.3390/antiox13111415 · Cited by 25
“However, it is likely to be some time before this drug becomes available worldwide [10].”
Wan, X., Ma, J., Bai, H., Hu, X., Ma, Y., Zhao, M., Liu, J., & Duan, J. (2025) · Biomolecules · doi:10.3390/biom15010140 · Cited by 27
Ravela, N., Shackelford, P., Blessing, N., Yoder, L., Chalasani, N., & Samala, N. R. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000670 · Cited by 26
“[2] 5] Starting in April 2024, resme-tirom became commercially available under the brand name Rezdiffra, but only through a handful of selected specialty pharmacies in the United States.”
InfluentialA person-centred clinical approach to the multimorbid patient with COPD
Celli, B. R., Fabbri, L. M., Yohannes, A. M., Hawkins, N. M., Criner, G. J., Bon, J. M., Humbert, M. J. C., Jenkins, C. R., Pantoni, L., Papi, A. A., et al. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.07.020 · Cited by 28
Ballantyne, C. M., & Norata, G. D. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf606 · Cited by 26
Bile acid signaling in MASLD: From pathogenesis to therapeutic applications
Simbrunner, B., Paternostro, R., Reiberger, T., & Trauner, M. (2025) · Hepatology · doi:10.1097/hep.0000000000001539 · Cited by 33
Targeting MASLD and MASH in the US Hispanic/Latino Population: A Review
Cumpian, N. A., Gutierrez, J. A., Wu, W., & Saab, S. (2025) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.4769 · Cited by 22
Microbiome−mediated crosstalk between T2DM and MASLD: a translational review focused on function
Jing, M., & Jiang, Y. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1677175 · Cited by 24
Pastena, F. D., Gautam, J., Lally, J., Fayyazi, R., Grasset, E., Bhattacharya, D., Fidelito, G., Ahmadi, E., Townsend, L. K., Batchuluun, B., et al. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2025.11.015 · Cited by 27
Samson, S. L., Vellanki, P., Blonde, L., Hirsch, I. B., Hoang, T. D., Isaacs, S. D., Izuora, K. E., Wang, C. C. L., Ooi, C. P., Padilla, B. I., et al. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.01.006 · Cited by 35
Ayesh, H., Beran, A., Suhail, S., Ayesh, S. K., & Niswender, K. D. (2024) · Biomedicines · doi:10.3390/biomedicines12102328 · Cited by 25
Health disparities in cirrhosis care and liver transplantation
Goldberg, D. J., Wilder, J. M., & Terrault, N. A. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-01003-1 · Cited by 26
“71).”
Advancing precision medicine in metabolic dysfunction-associated steatotic liver disease
Priego-Parra, B. A., Gallego‐Durán, R., Román-Calleja, B. M., Velasco, J. A. V.-R., Romero‐Gómez, M., & Gracia‐Sancho, J. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.03.006 · Cited by 28
Steatotic liver disease and cancer: from pathogenesis to therapeutic targets
Yang, Z., Liu, Z., Liu, W., & Dong, X. C. (2025) · eGastroenterology · doi:10.1136/egastro-2025-100218 · Cited by 33
Dissecting the mechanisms of MASLD fibrosis in the era of single-cell and spatial omics
Colella, F., Henderson, N. C., & Ramachandran, P. (2025) · Journal of Clinical Investigation · doi:10.1172/jci186421 · Cited by 31
“Series Editor: Scott L. Friedman”
Mechanisms and therapeutic insights into MASH-associated fibrosis
Zhu, Y., & Cai, B. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.09.004 · Cited by 32
Bastos, V. A. F., de Souza, A. G., Guedes, V. C. S., & Cunha, T. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199476 · Cited by 27
“In metabolic liver disease, the THR-β agonist resmetirom achieved ≥ 1-stage fibrosis improvement versus placebo in a phase 3 trial [168].”
Metabolic dysfunction-associated steatotic liver disease heterogeneity: Need of subtyping
Habib, S. (2024) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v15.i2.92791 · Cited by 24
Amorim, R., Soares, P., Chavarria, D., Benfeito, S., Cagide, F., Teixeira, J., Oliveira, P. J., & Borges, F. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116723 · Cited by 26
Xia, M., Varmazyad, M., Plá-Palacín, I., Gavlock, D. C., DeBiasio, R., LaRocca, G. M., Reese, C. E., Florentino, R. M., Faccioli, L. A. P., Brown, J. A., et al. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1423936 · Cited by 25
Miller, K. C., Geyer, B., Alexopoulos, A., Moylan, C. A., & Pagidipati, N. J. (2024) · Digestive Diseases and Sciences · doi:10.1007/s10620-024-08722-0 · Cited by 25
“Of note, nearly 90% of patients in the trial for Resmetirom were White, making it difficult to determine whether this therapy will show the same benefit in other racial and ethnic groups [54].”
Nielsen, M. H., Nøhr-Meldgaard, J., Møllerhøj, M. B., Oró, D., Pors, S. E., Andersen, M. W., Kamzolas, I., Petsalaki, E., Vacca, M., Harder, L. M., et al. (2024) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00110.2024 · Cited by 22
Singal, A. G., Quirk, L., Boike, J. R., Chernyak, V., Feng, Z., Giamarqo, G., Kanwal, F., Ioannou, G. N., Manes, S., Marrero, J. A., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000001203 · Cited by 31
Resmetirom: the first approved therapy for treating metabolic dysfunction associated steatohepatitis
Bhushan, S. R., Sohal, A., Noureddin, M., & Kowdley, K. V. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2478917 · Cited by 28
“However, free testosterone and thyrox-ine-binding globulin levels remained unchanged [42].”
InfluentialSelf-citationChu, Y., Yang, S., & Chen, X. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108844 · Cited by 22
Pecani, M., Andreozzi, P., Cangemi, R., Corica, B., Miglionico, M., Romiti, G. F., Stefanini, L., Raparelli, V., & Basili, S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14082750 · Cited by 29
“Additionally, concomitant use with certain statins may require dose adjustments of the statin and close monitoring for potential statin-related side-effects [184,185].”
Hepatoprotective Effect of Kaempferol—A Review
Niziński, P., Krajewska, A., Oniszczuk, T., Polak, B., & Oniszczuk, A. (2025) · Molecules · doi:10.3390/molecules30091913 · Cited by 28
Engineered Hydrogels for Organoid Models of Human Nonalcoholic Fatty Liver Disease
Liu, Y., Gilchrist, A. E., Johansson, P. K., Guan, Y., Deras, J. D., Liu, Y., Ceva, S., Huang, M. S., Navarro, R. S., Enejder, A. M. K., et al. (2025) · Advanced Science · doi:10.1002/advs.202417332 · Cited by 29
Kanda, T., Sasaki, R., Abé, H., Kimura, N., Yoshida, T., Hayashi, K., Sakamaki, A., Yokoo, T., Kamimura, H., Tsuchiya, A., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115164 · Cited by 25
Zargar, A. H., Bhansali, A. K., Majumder, A., Maheshwari, A., Bhattacharyya, A., Dasgupta, A., Saboo, B., Sethi, B. K., Sanyal, D., Seshadri, K., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16496 · Cited by 29
“Resmetirom has demonstrated improvement in hepatic fibrosis 88 and is approved by the Food and Drug Administration (FDA) for the treatment of NASH with fibrosis.”
Moncho, F., Benlloch, S., & Górriz, J. L. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf260 · Cited by 26
“Although renal and cardiovascular outcomes remain unstudied, reductions in apoB and LDL-C suggest potential cardiometabolic benefits [59 ].”
Caussy, C., Cusi, K. J., Rosenstock, J., Bugianesi, E., Thomas, M. K., Tang, Y., Mather, K. J., Loomba, R., Sanyal, A. J., & Hartman, M. L. (2025) · Diabetes Care · doi:10.2337/dc25-1306 · Cited by 33
Self-citation
Metadata
- Authors
- Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., Anstee, Q. M., Abdelmalek, M. F., Younossi, Z., Baum, S. J., Francque, S., Charlton, M. R., Newsome, P. N., Lanthier, N., Schiefke, I., Mangia, A., Pericàs, J. M., Patil, R., Sanyal, A. J., Noureddin, M., Bansal, M. B., Alkhouri, N., Castera, L., Rudraraju, M., & Ratziu, V.
- Affiliations
- University Hospitals Birmingham NHS Foundation Trust (GB)
- From the University of Oxford, Oxford (S.A.H.), the Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne (Q.M.A.), and the National Institute for Health Research, Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, Birmingham (P.N.N.) — all in the United Kingdom; Pinnacle Clinical Research, San Antonio (S.A.H., M.R.), South Texas Research Institute, Edinburg (R.P.), and Houston Methodist Hospital, Houston Research Institute, Houston (M.N.) — all in Texas; Liverpat and University of Paris (P.B.), INSERM, Unité Mixte de Recherche Scientifique (UMRS) 1139, Centre de Recherche sur l’Inflammation (L.C.), and Sorbonne Université, ICAN Institute for Cardiometabolism and Nutrition, Assistance Publique–Hôpitaux de Paris (APHP), INSERM, UMRS 1138, Centre de Recherche des Cordeliers (V.R.), Paris, and Université Paris-Cité, Department of Hepatology, Beaujon Hospital, APHP, Clichy (L.C.) — ...
- Universitat Autònoma de Barcelona (ES)
- Houston Methodist (US)
- ORCID
- Harrison, Stephen A.
- Guy, Cynthia D.
- Schattenberg, Jörn M.
- Loomba, Rohit
- Taub, Rebecca
- Neff, Guy W.
- Rinella, Mary E.
- Anstee, Quentin M.
- Abdelmalek, Manal F.
- Younossi, Zobair
- Baum, Seth J.
- Francque, Sven
- Charlton, Michael R.
- Newsome, Philip N.
- Lanthier, Nicolas
- Mangia, Alessandra
- Pericàs, Juan M.
- Patil, Rashmee
- Sanyal, Arun J.
- Noureddin, Mazen
- Bansal, Meena B.
- Alkhouri, Naim
- Rudraraju, Madhavi
- Ratziu, Vlad
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-02-08
- Volume
- 390
- Issue
- 6
- Pages
- 497-509
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4391592880
- Cited by
- 2,084
- References
- 26
- Citations by year
- 2026: 797 · 2025: 807 · 2024: 478
- FWCI
- 635.31
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Digital Access to Libraries (submittedVersion, other-oa)
- Digital Access to Libraries (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Open Access CRIS of the University of Bern
- Funders
- Madrigal Pharmaceuticals
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- resmetirom, nonalcoholic steatohepatitis, liver fibrosis, thyroid hormone receptor beta agonist, NASH resolution, fibrosis regression, NAFLD activity score, LDL cholesterol, triglycerides, cirrhosis prevention, drug safety and tolerability
- MeSH terms
- Adult, Biopsy, Dose-Response Relationship, Drug, Double-Blind Method, Humans, Liver, Liver Cirrhosis, Pyridazines, Uracil, Treatment Outcome, Thyroid Hormone Receptors beta, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.